Depo-Provera MDL 3140 update: settlement talks, Daubert hearing, and meningioma claims
If you have been following the Depo-Provera brain tumor lawsuits,
the last few weeks probably looked messy. That is not your
imagination.
There is a real settlement development in the federal case. There is
also a still-scheduled expert hearing. Both things can be true. For
a person who used Depo-Provera and later learned she had a
meningioma, the safest way to read the news is this: the litigation
is moving, but eligibility still depends on records and facts.
Depo-Provera MDL 3140: where the case stands
The federal cases are grouped in MDL No. 3140, In re: Depo-Provera
(Depot Medroxyprogesterone Acetate) Products Liability Litigation.
Judge M. Casey Rodgers is handling the MDL in the Northern District
of Florida.
The JPML transfer order is worth reading because it lays out the
basics in ordinary enough language. Plaintiffs allege that long use
of Depo-Provera, the injectable birth-control drug, can increase the
risk of intracranial meningioma. The Panel said the cases share
questions about causation, warnings, and what the companies knew or
should have known.
The numbers have changed a lot since the MDL started. The JPML
report dated July 1, 2026 lists MDL 3140 with 5,830 pending actions
and 5,916 total actions. That is a large docket, and it explains why
court orders about timing, eligibility, and expert proof matter so
much.
The June order says a global agreement exists for some claims
On June 15, 2026, Judge Rodgers entered Pretrial Order No. 30A. The
order says plaintiffs' leadership and Pfizer-related defendants
reached a global agreement. People with cases in the MDL who meet
the agreed eligibility criteria will have an opportunity to resolve
their claims.
That sentence has limits. The order does not say every Depo-Provera
meningioma case is settled. It says the agreement, once finalized,
will not resolve all cases in the MDL.
That is why the court did not simply shut down the science fight.
Judge Rodgers continued the Rule 702 hearing from June 24-25 to July
27, 2026 in Pensacola. A Rule 702, or Daubert, hearing is where the
court looks at whether expert opinions are reliable enough to be
used in the litigation.
So the practical takeaway is a little boring, but important:
settlement talks matter, and so does the July 27 expert hearing.
What kind of injury is being reviewed?
This MDL is about meningioma after Depo-Provera or generic depot
medroxyprogesterone acetate use.
A meningioma is a tumor involving the membranes around the brain or
spinal cord. Some are watched with repeat scans. Others lead to
surgery, radiation, vision changes, seizures, headaches, balance
problems, or years of follow-up appointments. A diagnosis can be
frightening even when a doctor uses words like "benign."
For claim review, the paper trail usually matters more than memory.
Helpful records can include:
- pharmacy printouts showing Depo-Provera or generic injections
- OB-GYN, clinic, or public health department injection records
- insurance or Medicaid records showing dates of treatment
- MRI or CT reports showing the meningioma
- neurology, neurosurgery, radiation, or oncology notes
- pathology records, if the tumor was removed
- death-related medical or estate records, if the patient passed away
Many people received shots every three months for years, sometimes
at more than one clinic. If that happened, records may be scattered.
That is normal. It just means the search may take a little patience.
What the medical sources add
The lawsuits are not based on a single news story. They lean heavily
on medical research and labeling developments.
A 2024 BMJ national case-control study reported an association
between prolonged use of injectable medroxyprogesterone acetate and
intracranial meningioma. Depo-Provera is an injectable
medroxyprogesterone acetate product, which is why the study is cited
so often in this litigation.
ACOG has also published counseling material for clinicians and
patients on birth-control injection and meningioma. Its guidance is
measured: patients should discuss personal risk, benefits, and
alternatives with a medical professional rather than making a sudden
change on their own.
The Pediatric Endocrine Society reported that the U.S. prescribing
information was updated in December 2025 to add warning language
about a potential increased risk of meningioma.
None of those sources proves that a specific person's tumor was
caused by Depo-Provera. They do show why this issue is now being
taken seriously in court and in medical counseling.
What to do if you think your case may fit
Start with dates. When did the injections begin? How often did you
receive them? When was the meningioma first seen on imaging? What
treatment did your doctor recommend?
Do not worry if you do not know every answer today. A rough timeline
is still useful. The next step is usually collecting records to
confirm the details.
Also, be careful with settlement rumors. Pretrial Order No. 30A
refers to an opportunity for eligible plaintiffs, but it does not
publish a guaranteed payout chart. A lawyer or intake company should
not promise a result before reviewing your medical and prescription
history.
Most important, do not stop or change medication because of a
lawsuit article. Talk to the clinician who knows your health
history.
Why the July 2026 update matters
Depo-Provera MDL 3140 is no longer in the early wait-and-see phase.
The docket is large. The court has acknowledged a settlement
framework for some eligible claims. The expert hearing is still set
for July 27, 2026.
For potential claimants and families, the best move is not panic. It
is documentation. Save what you have, request what you are missing,
and get a claim review based on records rather than guesses.
Mass Tort America can help review whether a Depo-Provera and
meningioma history may fit the current litigation. A review is not a
promise that a claim will qualify, and it is not a promise of money.
Informational and attorney advertising disclaimer
This article is for general information and may be attorney
advertising. It is not medical advice. It is not a guarantee of
compensation, settlement, or legal outcome. Every claim depends on
medical records, exposure history, deadlines, and the law that
applies to that claim.
Sources checked for this update: JPML MDL No. 3140 transfer order;
Northern District of Florida MDL page; Judge Rodgers' June 15, 2026
Pretrial Order No. 30A; JPML pending-MDL report dated July 1, 2026;
ACOG counseling material on birth-control injection and meningioma;
Pediatric Endocrine Society summary of the Depo-Provera label
update; current Lawsuit Information Center litigation reporting.
